CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Note Receivable from Sale of Stock [Member]	Accumulated Deficit [Member]	Total
Balances at beginning at Mar. 31, 2014	$ 500			$ 1,300	$ 62,001,400	$ (3,968,100)	$ (198,100)	$ (70,636,900)	$ (12,799,900)
Balances at beginning (in shares) at Mar. 31, 2014	500,000			1,310,109
Allocated proceeds from sale of common stock Units for cash under 2014 Unit Private Placement, including beneficial conversion feature				$ 300	2,746,800				2,747,100
Allocated proceeds from sale of common stock Units for cash under 2014 Unit Private Placement, including beneficial conversion feature (in shares)				280,350
Share-based compensation expense					2,460,100				2,460,100
Payment on and settlement of note receivable from sale of stock							$ 198,100		198,100
Incremental fair value of modified warrants					98,400				98,400
Fair Value of common stock issued for services				$ 100	635,600				635,700
Fair Value of common stock issued for services (in shares)				71,667
Fair value of common stock and warrants issued in settlement oftechnology license expenses					230,200				230,200
Fair value of common stock and warrants issued in settlement oftechnology license expenses (in shares)				15,000
Fair value of warrants issued to Morrison & Foerster, Cato Research Ltd. and University Health Network in connection with accruedinterest on underlying notes					44,400				44,400
Effect of amendments of 2013 Unit Notes and warrants, including repurchase of beneficial conversion feature					109,300				109,300
Effect of amendments of PLTG Senior Secured Promissory Notes, including repurchase of beneficial conversion feature					(380,400)				(380,400)
Net loss								(13,885,800)	(13,885,800)
Balances at end at Mar. 31, 2015	$ 500			$ 1,700	67,945,800	(3,968,100)		(84,522,700)	(20,542,800)
Balances at end (in shares) at Mar. 31, 2015	500,000			1,677,126
Allocated proceeds from sale of common stock Units for cash under 2014 Unit Private Placement, including beneficial conversion feature					277,200				277,200
Allocated proceeds from sale of common stock Units for cash under 2014 Unit Private Placement, including beneficial conversion feature (in shares)				33,000
Proceeds from sale of Series B Preferred Units for cash under 2015 Series B Preferred Unit Private Placement		$ 700			5,025,100				5,025,800
Proceeds from sale of Series B Preferred Units for cash under 2015 Series B Preferred Unit Private Placement (in shares)		717,978
Share-based compensation expense					4,041,400				4,041,400
Conversion of Senior Secured and subordinate promissory notes into Series B Preferred stock, including recapture of beneficial conversion feature upon conversion		$ 3,100			42,577,100				42,580,200
Conversion of Senior Secured and subordinate promissory notes into Series B Preferred stock, including recapture of beneficial conversion feature upon conversion (in shares)		3,018,917
Elimination of warrant liability resulting from modification of PLTG Warrants					4,903,100				4,903,100
Exchange of common stock for Series B Preferred stock (in shares)		30,000		(30,000)
Accrued dividends on Series B Preferred stock					(2,140,500)				(2,140,500)
Conversion of Series B Preferred stock into common stock, including common stock issued in payment of accrued dividends		$ (200)		$ 200	50,900				50,900
Conversion of Series B Preferred stock into common stock, including common stock issued in payment of accrued dividends (in shares)		(228,818)		235,655
Exchange of common stock for Series C Preferred stock			$ 200	$ (200)
Exchange of common stock for Series C Preferred stock (in shares)			200,000	(200,000)
Exchange of outstanding warrants for Series C Preferred stock			$ 2,100		3,192,800				3,194,900
Exchange of outstanding warrants for Series C Preferred stock (in shares)			2,118,012
Exchange of outstanding warrants for common stock and other warrant modifications				$ 800	3,022,300				3,023,100
Exchange of outstanding warrants for common stock and other warrant modifications (in shares)				814,989
Fair value of common stock, Series B Preferred stock and warrants granted for services		$ 100		$ 100	3,829,800				3,830,000
Fair value of common stock, Series B Preferred stock and warrants granted for services (in shares)		125,000		92,375
Net loss								(47,220,500)	(47,220,500)
Balances at end at Mar. 31, 2016	$ 500	$ 3,700	$ 2,300	$ 2,600	$ 132,725,000	$ (3,968,100)		$ (131,743,200)	$ (2,977,200)
Balances at end (in shares) at Mar. 31, 2016	500,000	3,663,077	2,318,012	2,623,145